The Question Behind the Question
You have a well-differentiated, Grade 1 neuroendocrine tumor (NET) that has spread. Your scans show disease in the liver, lymph nodes, or other areas. But you feel okay. Your doctor says the team can watch it for now. Another specialist says you should start treatment soon. You're not sure who is right.
This kind of uncertainty is common among people with low-grade NETs. Grade 1 tumors grow slowly. They often behave differently from other cancers. This makes timing confusing and complicated.
This article reviews research on observation versus treatment for metastatic, well-differentiated Grade 1 neuroendocrine tumors, including Lu-177 DOTATATE.
What Grade 1 Means — and Why It Changes the Conversation
Neuroendocrine tumors are graded based on how fast tumor cells divide. A key marker is called Ki-67. It measures what percentage of tumor cells are actively multiplying at a given moment.
- Grade 1 (G1): Ki-67 index below 3%. Very low cell division rate.
- Grade 2 (G2): Ki-67 index between 3% and 20%. Moderate rate.
- Grade 3 (G3): Ki-67 above 20%. High cell division rate.
According to the Neuroendocrine Tumor Research Foundation (NETRF), grade helps predict how a tumor will behave over time. Grade 1 tumors grow slowly and are well-differentiated. This is why doctors sometimes watch the tumor before starting systemic therapy.
But "slow-growing" does not mean "harmless." A Grade 1 tumor that has spread to the liver, bones, or lymph nodes is still metastatic cancer. Good NET care means finding the right moment to start treatment.
What "Watch and Wait" Actually Looks Like
For people with metastatic Grade 1 NETs, observation is an accepted initial approach in some situations. This is not the same as doing nothing.
During a watch-and-wait period, you will typically:
- Have imaging scans (CT, MRI, or DOTATATE PET) every 3 to 6 months
- Have blood and urine tests to track tumor markers like chromogranin A and 5-HIAA
- Attend regular visits with your oncologist or a dedicated NET specialist
- Track any new or changing symptoms and report them to your team between appointments
A review in PubMed Central of watch-and-wait approaches for advanced neuroendocrine tumors found that this approach works for well-differentiated Grade 1 NETs that are non-functioning, low-volume, and cause few or no symptoms. The review found that some of these tumors stayed stable for months or years in the placebo arm of clinical trials. This suggests some Grade 1 tumors don't progress for a long time. For those patients, starting treatment right away could cause side effects without helping.
Observation is not permanent. It gives your team time to understand how your tumor actually behaves before starting treatments that have their own risks and side effects.
When Watching Is No Longer the Right Call
Observation doesn't work for everyone, and even when it does, it doesn't last forever. Several signals may prompt your team to recommend starting treatment:
- Radiological progression: Scans show tumors growing in size or number
- Worsening symptoms: New or increasing diarrhea, flushing, abdominal pain, or significant fatigue linked to the tumor
- High tumor burden: A large number of metastatic sites or disease involving critical organs like the liver at high volume
- Rising tumor markers: Significant increases in chromogranin A or other markers suggesting the tumor is becoming more active
- Hormone-related symptoms from a functioning tumor: If the tumor releases hormones that are meaningfully affecting daily life and cannot be adequately managed with supportive care alone
The decision to move from watching to treating is made case by case. The goal is to catch real progression early, but avoid treatment side effects when they're not yet needed.
Where Somatostatin Analogs Often Come First
Before Lu-177 DOTATATE, most treatment guidelines recommend somatostatin analogs (SSAs) as a first treatment for metastatic, well-differentiated NETs. SSAs mimic a natural hormone that can slow tumor growth and control symptoms like flushing and diarrhea. They're typically given as monthly injections and usually have manageable side effects.
The landmark CLARINET Phase III clinical trial found that a somatostatin analog significantly extended progression-free survival compared to placebo in patients with metastatic Grade 1 and Grade 2 NETs. A review of the CLARINET findings in PubMed Central found that these results questioned the standard "watch and wait" approach and supported SSAs as a first-line treatment for tumor control in stable or progressive GEP-NETs with lower Ki-67 values.
What this means for you: if you have a Grade 1 NET and your team decides it's time to start treatment, SSAs are usually the first step, not Lu-177 DOTATATE. PRRT usually comes later.
If you are wondering how SSAs and Lu-177 DOTATATE may work together as part of a longer treatment plan, see our article on combining Lu-177 DOTATATE with somatostatin analogs for carcinoid tumors.
Where Lu-177 DOTATATE Enters the Picture
Lu-177 DOTATATE (also called Peptide Receptor Radionuclide Therapy or PRRT) is a targeted form of radiation therapy. It works by attaching to somatostatin receptors on tumor cells and delivering a precise dose of radiation directly to those cells, while sparing much of the surrounding healthy tissue.
According to the Neuroendocrine Tumor Research Foundation, PRRT is an advance in NET treatment, especially for tumors that express somatostatin receptors, which most well-differentiated Grade 1 NETs do.
The FDA approved Lu-177 DOTATATE in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic NETs (GEP-NETs), based largely on results from the NETTER-1 clinical trial. That trial included patients with progressive, well-differentiated midgut NETs (Grade 1 and Grade 2) who had already progressed on SSA therapy. As described in StatPearls via the National Institutes of Health, typical eligibility criteria for Lu-177 DOTATATE include confirmed somatostatin receptor positivity on a Gallium-68 DOTATATE PET scan, a Ki-67 below 20%, adequate kidney function, and acceptable blood cell counts.
This matters for Grade 1 patients: the standard approval pathway was built for patients who had already tried SSAs and progressed. For most people, Lu-177 DOTATATE is not the first treatment. It usually comes after other options have been tried or are no longer working.
Some NET specialists and research are exploring whether earlier PRRT (before SSA failure) might help certain patients. Evidence hasn't yet built up enough for a universal recommendation. It's worth discussing with your specialist.
If your NET diagnosis is recent and you are wondering whether you need to wait before accessing PRRT, our article on early access to Lu-177 DOTATATE for newly diagnosed NETs explores this question in more detail.
Key Factors Your Team Will Weigh
Treatment timing for Grade 1 NETs is not a formula. It is a judgment call based on the specifics of your case. Here are the main factors your oncologist and NET specialists will consider:
- Tumor growth rate: Serial scans over time reveal whether tumors are growing, stable, or shrinking. Faster growth may push toward earlier treatment.
- Ki-67 index: Even within the Grade 1 range, a Ki-67 near 3% may behave differently than one close to 1%. Borderline values matter.
- Somatostatin receptor uptake on imaging: A Gallium-68 DOTATATE PET scan shows how strongly your tumors express the receptor that PRRT targets. Strong uptake is essential for PRRT to be effective. Low or absent uptake may make Lu-177 DOTATATE less appropriate for your tumor.
- Tumor burden and location: Extensive liver involvement or disease involving critical structures may prompt earlier intervention.
- Symptom burden: If the tumor is producing hormones that are affecting your quality of life, treatment is generally started sooner rather than later.
- Kidney function and blood counts: These are important gatekeepers for PRRT eligibility. Some patients may not qualify for Lu-177 DOTATATE for reasons unrelated to tumor grade. To understand what specific labs and scans are needed, see our article on what lab results and scans are required before starting Lu-177 DOTATATE for a well-differentiated neuroendocrine tumor.
- Your overall health and personal goals: Treatment decisions are not made in isolation. Your other health conditions, quality-of-life priorities, and personal preferences are part of every meaningful conversation with your care team.
Grade 1 Does Not Mean Identical
One thing that surprises many patients: Grade 1 NETs are not all alike. Tumor growth rates in Grade 1 vary considerably from person to person. Some Grade 1 tumors stay stable for years. Others progress faster than expected. Some patients also find their tumor's grade changes over time, called grade progression. A tumor that was Grade 1 can become Grade 2 on a later biopsy. This is why ongoing monitoring matters even when things appear well-controlled.
It also means you shouldn't compare your treatment plan to someone else's, even if you both have a Grade 1 diagnosis. Your specific tumor, how it looks on imaging, and your overall health determine your treatment plan.
What Research Is Still Working Out
Researchers haven't yet determined the exact right time to use Lu-177 DOTATATE in treatment for Grade 1 NETs. They're working to figure out which patients benefit from earlier PRRT versus starting with SSAs first. Clinical trials are ongoing, and guidelines continue to evolve based on new data.
What is reasonably clear from the current evidence: watch and wait is a supported strategy for a subset of Grade 1 patients, particularly those with stable, low-volume, non-functional disease and no rapid progression on serial imaging. For those patients, early PRRT might cause radiation side effects without helping them more than careful observation. But for Grade 1 patients with documented progressive disease, high tumor burden, or significant symptoms, moving toward active treatment including eventually PRRT is appropriate and may be time-sensitive.
You Are Not Passive in This Process
Even if your team recommends observation for now, you can take an active role. Ask your care team the following questions at your next visit:
- How often will I have scans, and what specific findings would prompt a move to treatment?
- Do I have a Gallium-68 DOTATATE PET scan on record, and does my tumor show strong somatostatin receptor expression?
- Should I be on a somatostatin analog now, even if we are not starting PRRT?
- At what point would you recommend Lu-177 DOTATATE, and what would change that recommendation?
- Am I eligible for any clinical trials during this observation period?
A second opinion from a NET specialist or from a center with experience in PRRT can help you know whether the observation approach is right for your case or whether it's time to move forward.
When to Talk to Your Doctor
Contact your care team promptly if you notice new or worsening symptoms, such as increased flushing, more frequent diarrhea, new abdominal pain, significant fatigue, or unexplained weight loss. These can be signs that your tumor is becoming more active. Do not wait for your next scheduled appointment if something feels different from your baseline.
If you've been on observation for a while without a recent DOTATATE PET scan or rebiopsy, ask your team whether you should get updated imaging or pathology to check your tumor's current grade and receptor status before making any treatment decisions.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
My Grade 1 NET has been stable on scans for two years. Is it still safe to keep watching?
Stability over two years is a meaningful finding, and it is one reason observation may continue to be appropriate for you. That said, stable does not always mean unchanging forever. Your team will use serial imaging and tumor markers to watch for any shift in your tumor's behavior. If scans remain stable and you have no new or worsening symptoms, continued observation may well be the right call. If something changes — in your scans, your markers, or how you feel — your team can move to treatment. Ask your doctor specifically how often they recommend imaging and what they would need to see to recommend a change in strategy.
Do I need a Gallium-68 DOTATATE PET scan before Lu-177 DOTATATE is even an option?
Yes. A DOTATATE PET scan — or equivalent somatostatin receptor imaging — is essential before PRRT can be considered. It shows whether your tumor cells express the somatostatin receptor that Lu-177 DOTATATE targets. If receptor expression is absent or very low on imaging, the therapy is unlikely to reach and affect your tumor effectively. This scan is typically required as part of PRRT eligibility evaluation. Most Grade 1 NETs do express this receptor, but confirming it with current imaging is important before any treatment decision is made.
My doctor wants to start a somatostatin analog before considering Lu-177 DOTATATE. Is that the correct order?
For most patients with metastatic Grade 1 NETs, this sequencing reflects current evidence-based practice. The CLARINET trial showed that somatostatin analogs may slow tumor growth in stable or progressive Grade 1 and Grade 2 GEP-NET disease. Lu-177 DOTATATE has typically been studied and approved for patients who have already progressed on SSA therapy. That said, the field is evolving, and some centers are exploring earlier PRRT use. The best approach depends on your specific tumor characteristics, growth rate, receptor status, and overall health. Your NET specialist can help determine which sequence fits your case.
What if my tumor grade changes from Grade 1 to Grade 2 — does that change my treatment options?
It can. Grade progression — where a tumor that was Grade 1 becomes Grade 2 on a later biopsy — does happen in a subset of NET patients and may signal that the disease is becoming more active. A higher grade can affect which treatments are most appropriate and may make starting or changing therapy more urgent. If your team notices a significant rise in Ki-67 on a rebiopsy, or if your imaging changes significantly, this would typically prompt a full review of your treatment plan. It is one of the reasons periodic reassessment, including updated pathology when appropriate, is part of careful NET follow-up.
Can I access Lu-177 DOTATATE in India if I want PRRT sooner than my local doctors recommend?
India has developed a number of experienced centers that offer Lu-177 DOTATATE therapy, and it has become a destination for patients from within India and internationally seeking access to PRRT. If you are considering this, speak with your current oncologist first. You will need up-to-date scan reports, pathology slides confirming grade and somatostatin receptor status, a recent DOTATATE PET scan, and current lab results to share with any center you consult. Treatment timing decisions — including whether you are ready for PRRT or should continue on observation or SSA therapy — should still be guided by your clinical picture, not solely by geography or access.